Status:

COMPLETED

Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis

Lead Sponsor:

Medical University of Graz

Conditions:

Primary Biliary Cirrhosis

Hypercholesterolemia

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

Primary biliary cirrhosis (PBC) is frequently associated with hypercholesterolemia and possibly with an increased cardiovascular morbidity and mortality. Statins lower serum cholesterol levels and may...

Detailed Description

Primary biliary cirrhosis (PBC) is often associated with abnormalities in serum lipids. Hypercholesterolemia is an established risk factor for cardiovascular morbidity and mortality. Since many PBC pa...

Eligibility Criteria

Inclusion

  • LDL-cholesterol \> 130 mg/dl
  • Primary biliary cirrhosis (AMA positive or biopsy proven)
  • Male or female gender
  • Age 18-70 years
  • Normal kidney function

Exclusion

  • Primary biliary cirrhosis Stage III-IV (Ludwig Score)
  • Liver cirrhosis
  • Decompensated liver disease ( \> Child-Pugh class B, ascites, esophageal varices)
  • ALT or AST \> 2x ULN
  • Pregnancy or breastfeeding
  • Premenopausal women without certain contraception
  • Known hypersensitivity to HMG-CoA reductase inhibitors
  • Current treatment with lipid-lowering agents other than atorvastatin; immunosuppressants, macrolides

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2007

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00844402

Start Date

January 1 2006

End Date

November 1 2007

Last Update

February 16 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Internal Medicine, Medical University of Graz

Graz, Austria, 8036